-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;text-align:justify;white-space:normal;line-height:27.
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">544px;">March 8,544px;">544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">The 544px;box-sizing:border-box ;overflow-wrap:break-word ;">first half of 544px;box-sizing:border-box ;overflow-wrap:break-word ;">2020 Chinese public medical institutions terminal the 544px;box-sizing:border-box ;overflow-wrap:break-word ;">first half of 544px;box-sizing:border-box ;overflow-wrap:break-word ;">2020544px;box-sizing:border-box ;overflow-wrap:break-word ;">544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
Fosapitant Dimeglumine for Injection544px;'>544px;">
And vomiting, this product has become an essential antiemetic drug for the prescription combination for the treatment of tumors.
Data show that fosapitan for injection is a neurokinin-1 (NK-1) receptor antagonist and a prodrug of aprepitant, which is clinically used to prevent nausea caused by chemotherapeutics.
qq.
com/s/yCZooU4VaIlakyStHF15cg" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:15px;letter-spacing:0.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">According to data from 544px;box-sizing:border-box ;overflow-wrap:break-word ;">Menet.
com, in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals544px;box-sizing:border-box ;overflow-wrap:break-word ;">The 544px;box-sizing:border-box ;overflow-wrap:break-word ;">sales of fosapitant dimeglumine injections have 544px;box-sizing:border-box ;overflow-wrap:break-word ;">grown rapidly, approaching 20 million yuan in the first half of 2020.
Among them, CP Tianqing Pharmaceutical Group has the largest market share, exceeding 50%.
At present , there are three manufacturers of 544px;box-sizing:border-box ;overflow-wrap:break-word ;">fosapitan and dimeglumine for 544px;box-sizing:border-box ;overflow-wrap:break-word ;">injection .
Among them, Jiangsu Hausen Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group were approved in the second half of 2019; 544px;box-sizing:border-box ;overflow-wrap:break-word ;">Qilu Pharmaceutical was approved for listing in February this year .
weixin.
qq.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">
comSource: One-click search on Mi Nei.
com
544px;box-sizing:border-box ;overflow-wrap:break-word ;">Chia Tai Tianqing Pharmaceutical Group is reviewing and approving supplementary applications; Qilu Pharmaceutical (Hainan) and Shandong Luoxin Pharmaceutical Group are reviewing and approving listing applications submitted in generic 3 categories.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">Consistency evaluation, injected with fosaprepitant double meglumine only Jiangsu Stockhausen medicine to generic Class 3 approval and Qilu Pharmaceutical, and deemed too comment.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">544px;box-sizing:border-box ;overflow-wrap:break-word ;">
China Biopharmaceuticals stated that the approval of fosapitant dimeglumine for injection in the United States is another achievement of the group's internationalization strategy, which once again proves the group's determination and ability to enter the overseas high-end market.
The listing of this product will further accelerate the Group's process of expanding the international market of oncology drugs, paving the way for the subsequent promotion of a series of high-end generic drugs in the overseas market.
544px;">March 8,544px;">China Biopharmaceuticals issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the US FDA for a new drug application (ANDA) Application), this is another "three reports and three batches" variety harvested by the group.
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">
544px;">
544px;">March 8,544px;">China Biopharmaceuticals issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the US FDA for a new drug application (ANDA) Application), this is another "three reports and three batches" variety harvested by the group.
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">
544px;">
544px;">March 8,544px;">China Biopharmaceuticals issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the US FDA for a new drug application (ANDA) Application), this is another "three reports and three batches" variety harvested by the group.
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">
544px;">
544px;">March 8,544px;">China Biopharmaceuticals issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the US FDA for a new drug application (ANDA) Application), this is another "three reports and three batches" variety harvested by the group.
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">
544px;">
544px;">544px;"> 544px;">March 8,544px;">China Biopharmaceuticals issued an announcement that the drug "Fosapitant Dimeglumine for Injection" (trade name: Shanqi) developed by the group to prevent nausea and vomiting caused by chemotherapy has been approved by the US FDA for a new drug application (ANDA) Application), this is another "three reports and three batches" variety harvested by the group.
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">
This variety has been approved for listing in the three major international markets of China, the United States and Europe.
Meters within the network data show that 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">in 2020 544px;box-sizing:border-box ;overflow-wrap:break-word ;">the first half of public medical institutions terminal China544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
At present, there are three domestic manufacturers of fosapitan and dimeglumine for injection: Jiangsu Haosen Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, and Qilu Pharmaceutical.
544px;'>544px;">544px;">March 8,544px;">544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;">The 544px;box-sizing:border-box ;overflow-wrap:break-word ;">first half of 544px;box-sizing:border-box ;overflow-wrap:break-word ;">2020 Chinese public medical institutions terminal the 544px;box-sizing:border-box ;overflow-wrap:break-word ;">first half of 544px;box-sizing:border-box ;overflow-wrap:break-word ;">2020544px;box-sizing:border-box ;overflow-wrap:break-word ;">544px;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;box-sizing:border-box ;overflow-wrap:break-word ;'>The 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>sales volume of 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>fosapitant dimeglumine 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>injection is 544px;box-sizing:border-box ;overflow-wrap:break-word ;'>close to 20 million yuan.
Among them, CP Tianqing Pharmaceutical Group has the largest market share.
Fosapitant Dimeglumine for Injection544px;'>544px;">
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Data show that fosapitan for injection is a neurokinin-1 (NK-1) receptor antagonist and a prodrug of aprepitant, which is clinically used to prevent nausea caused by chemotherapeutics.
And vomiting, this product has become an essential antiemetic drug for the prescription combination for the treatment of tumors.
Data show that fosapitan for injection is a neurokinin-1 (NK-1) receptor antagonist and a prodrug of aprepitant, which is clinically used to prevent nausea caused by chemotherapeutics.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> Sales of fosapitan and dimeglumine injections in public medical institutions in China
Chinese public medical institutions terminal fosaprepitant dimeglumine double injection sales fosaprepitant double meglumine544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> 544px;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Source: 544px;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Terminal competition landscape of China's public medical institutions
544px;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Source: 544px;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;">Terminal competition landscape of China's public medical institutions544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> weixin.
qq.
com/s/yCZooU4VaIlakyStHF15cg" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;font-size:15px;letter-spacing:0.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">According to data from 544px;box-sizing:border-box ;overflow-wrap:break-word ;">Menet.
com, in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals544px;box-sizing:border-box ;overflow-wrap:break-word ;">The 544px;box-sizing:border-box ;overflow-wrap:break-word ;">sales of fosapitant dimeglumine injections have 544px;box-sizing:border-box ;overflow-wrap:break-word ;">grown rapidly, approaching 20 million yuan in the first half of 2020.
Among them, CP Tianqing Pharmaceutical Group has the largest market share, exceeding 50%.
At present , there are three manufacturers of 544px;box-sizing:border-box ;overflow-wrap:break-word ;">fosapitan and dimeglumine for 544px;box-sizing:border-box ;overflow-wrap:break-word ;">injection .
Among them, Jiangsu Hausen Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group were approved in the second half of 2019; 544px;box-sizing:border-box ;overflow-wrap:break-word ;">Qilu Pharmaceutical was approved for listing in February this year .
weixin.
qq.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:right;box-sizing:border-box ;'> Source: One-click search on Mi Nei.
comSource: One-click search on Mi Nei.
com
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> 544px;box-sizing:border-box ;overflow-wrap:break-word ;">
544px;box-sizing:border-box ;overflow-wrap:break-word ;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'> 544px;box-sizing:border-box ;overflow-wrap:break-word ;">Consistency evaluation, injected with fosaprepitant double meglumine only Jiangsu Stockhausen medicine to generic Class 3 approval and Qilu Pharmaceutical, and deemed too comment.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">Chia Tai Tianqing Pharmaceutical Group is reviewing and approving supplementary applications; Qilu Pharmaceutical (Hainan) and Shandong Luoxin Pharmaceutical Group are reviewing and approving listing applications submitted in generic 3 categories.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">Consistency evaluation, injected with fosaprepitant double meglumine only Jiangsu Stockhausen medicine to generic Class 3 approval and Qilu Pharmaceutical, and deemed too comment.
544px;box-sizing:border-box ;overflow-wrap:break-word ;">544px;box-sizing:border-box ;overflow-wrap:break-word ;">
China Biopharmaceuticals stated that the approval of fosapitant dimeglumine for injection in the United States is another achievement of the group's internationalization strategy, which once again proves the group's determination and ability to enter the overseas high-end market.
The listing of this product will further accelerate the Group's process of expanding the international market of oncology drugs, paving the way for the subsequent promotion of a series of high-end generic drugs in the overseas market.
